$TENX News
Last published 6d ago
- 6d agoTENXTENAX THERAPEUTICS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoTENXTenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireCompleted Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026
- 2mo agoTENXTenax Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferenceGlobeNewswireCHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company") announced today that Chris Giordano, President
- 2mo agoTENXTenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026GlobeNewswireIn patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112) In the same patient population, TNX-103 produced a 47%
- 3mo agoTENXTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEFGlobeNewswireTNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo In prespecified exploratory analyses in the overall trial population, treatment with TNX-103
- 3mo agoTENXTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireCompany expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax
- 4mo agoTENXTenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical
- 4mo agoTENXTenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026GlobeNewswireAbstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics,
- 6mo agoTENXTenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireOn track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team
- 6mo agoTENXTenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights
- 6mo agoTENXTenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial OfficerGlobeNewswireCHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights
- 6mo agoTENXTenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial OfficerGlobeNewswireMr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax
- 8mo agoTENXTenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireAchieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug
- 8mo agoTENXTenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare ConferenceGlobeNewswireCHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical
- 9mo agoTENXTenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026GlobeNewswireCHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical
- 10mo agoTENXTenax Therapeutics Announces Result of Prespecifed Blinded Sample Size AssessmentGlobeNewswirePlanned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3
- 11mo agoTENXTenax Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireCHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to
- 12mo agoTENXTenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 Tenax to
- 1y agoTENXTenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEFGlobeNewswireCHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to
- 1y agoTENXTenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceGlobeNewswireCHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to
- 1y agoTENXTenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEFGlobeNewswireProvides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also Provides Patent
- 1y agoTENXTenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025GlobeNewswireCHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to
- 1y agoTENXTenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL
- 1y agoTENXTenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL,
- 1y agoTENXTenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireCHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to
- 1y agoTENXTenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswireSuccessfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027 Phase 3
- 1y agoTENXTenax Therapeutics Announces $25 Million Private PlacementGlobeNewswireCHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) (the "Company" or "Tenax Therapeutics"), a Phase 3, development-stage pharmaceutical company using clinical insights to
- 1y agoTENXTenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEFGlobeNewswireAmendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025 Agreement by FDA to Initiate Second Global Phase 3 Study, LEVEL-2, with
- 1y agoTENXTenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare ConferenceGlobeNewswireCHAPEL HILL, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company focused on identifying,
- 1y agoTENXTenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech ConferenceGlobeNewswireCHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company focused on identifying,
- 1y agoTENXTenax Therapeutics Appoints Gillian Andor Vice President, Clinical OperationsGlobeNewswireCHAPEL HILL, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company focused on identifying,
- 1y agoTENXTenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript)Earnings Call Transcripts
- 1y agoTENXTenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewswireRaised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative Sites Now Initiated
- 2y agoATNMRDHLAVTXTENXActinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of DirectorsPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs)...
- 2y agoTENXTenax Therapeutics to Present at the Guggenheim Healthcare Innovation ConferenceGlobeNewswireCHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that
- 2y agoTENXTenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewswireRaised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 39 Investigative Sites Initiated In
- 2y agoTENXTenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 ProgramGlobeNewswire• Funding supports advancement of oral levosimendan (TNX-103) Phase 3 development program, including completion of the ongoing LEVEL Study for the treatment of Pulmonary Hypertension Due to Heart Failure with Preserved
- 2y agoTENXTenax Therapeutics Announces Oversubscribed $100 Million Private PlacementGlobeNewswireCHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) (the "Company" or "Tenax Therapeutics"), a Phase 3, development-stage pharmaceutical company focused on identifying,
- 2y agoTENXTenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewswireCurrently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded
- 2y agoTENXTenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewswireBroadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEFProvides U.S. intellectual property (IP) protection until December 2040, and
- 2y agoTENXTenax Therapeutics to Host KOL Event: "LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study"GlobeNewswirePanel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and the
- 2y agoTENXTenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ResultsGlobeNewswireFirst Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S.
- 2y agoTENXTenax Therapeutics to Present at the 36th Annual Roth ConferenceGlobeNewswireCHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that
- 2y agoTENXTenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024GlobeNewswireDr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved
- 2y agoTENXTenax Therapeutics Announces Pricing of Approximately $9 Million Public OfferingGlobeNewswireCHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address
- 2y agoTENXTenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewswireOver 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study LEVEL is a randomized, controlled Phase 3 trial of 152 patients, and will recruit patients primarily from leading research centers with large
- 2y agoTENXTenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewswireOnce granted, this patent will: provide U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040broaden IP protection for oral
- 2y agoTENXTenax Therapeutics Announces Reverse Stock SplitGlobeNewswireCHAPEL HILL, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address
- 2y agoTENXTenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory BoardGlobeNewswireCHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address
- 2y agoTENXTenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023GlobeNewswireFirst Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q 2023 (The LEVEL Study)FDA agreement that 6MWD will be the primary endpoint for both Phase 3 studies Phase 3 program designed to satisfy FDA's request for